| Metric | Value ($ M) | Q1 FY26 |
|---|---|---|
| Revenue | 265.71 | 6.5% |
| Total Income | 265.71 | 6.5% |
| Expenditure | 213.19 | 19.9% |
| PBT | — | |
| Net Profit | 29.18 | 38.5% |
| OPM | 19.77% | 8.99pp |
| NPM | 10.98% | 8.04pp |
| EPS | 0.61 | 36.5% |
Prestige Consumer Healthcare Reports Q1 FY27 Results, Raises FY27 Outlook
06 Aug 2026 · 6 Aug, 3:43 pm
Summary
Prestige Consumer Healthcare Inc. reported first quarter fiscal 2027 results with revenue of $265.7 million, a 6.5% increase year-over-year, driven by 3.2% organic sales growth. Adjusted Diluted EPS was $0.98, up from $0.95 in the prior year, supported by record Adjusted Free Cash Flow of $83.7 million. The company has raised its fiscal 2027 outlook to reflect the recent acquisitions of Breathe Right® and LaCorium, now projecting revenues between $1,290 to $1,315 million and Adjusted Diluted EPS between $4.55 to $4.65.
Key Highlights
- 1
Q1 Revenue reached $265.7 million, marking a 6.5% increase compared to the prior year.
- 2
Organic sales growth for Q1 was 3.2%, exceeding expectations.
- 3
Diluted Earnings Per Share (EPS) for Q1 was $0.61, with Adjusted Diluted EPS at $0.98, up from $0.95 in the prior year.
- 4
Q1 Cash from Operating Activities was $70.8 million, and Q1 Adjusted Non-GAAP Free Cash Flow reached a record $83.7 million.
- 5
The company successfully closed the Breathe Right® and LaCorium acquisitions in June and July, respectively.
- 6
The fiscal 2027 outlook has been raised to anticipate revenue between $1,290 to $1,315 million and Adjusted Diluted EPS between $4.55 to $4.65.
Management Comments
Ron Lombardi
First quarter performance exceeded our sales and earnings expectations, helped by strength across multiple categories that more than offset a challenging consumer backdrop and Clear Eyes® variability. We were also pleased to close the Breathe Right® acquisition late in the quarter, which added an incremental $6 million in revenue and is positioned well for long-term growth. These strong business results generated robust record adjusted free cash flow in the first quarter, leaving us well positioned to rapidly deleverage in the quarters ahead. Our strong initial first quarter performance gives us momentum in both revenue and earnings for full-year fiscal 2027. Our consumption remains healthy for our leading, trusted brands, and we continue to emphasize our proven marketing tactics to succeed in a challenging consumer environment. In addition, our portfolio diversity and business attributes leave us well positioned to manage the continued volatile supply for Clear Eyes®. We are very excited about our recently closed Breathe Right portfolio and LaCorium Health acquisitions in mid-June and July, respectively, and both bring strong long-term growth prospects. Breathe Right® is a category-defining, global brand in the attractive better-breathing space, where we expect to grow the category domestically while expanding the brand's international presence. LaCorium's Dermal Therapy® brand is a leader in therapeutic skin care in Australia, and we anticipate strong sales growth under the Prestige Consumer Healthcare business model, driven by category growth, innovation, and continued geographic expansion. We are raising our fiscal 2027 financial outlook for both revenue and EPS, entirely to account for the addition of these two businesses. These acquisitions add nearly 20% to our revenue base and we expect the acquisitions to become increasingly accretive to profitability and cash flow as we move past the near-term and begin to realize business synergies and our brand growth objectives.
Informational and educational content only. Not investment advice.